The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling

Nature Communications

Volumn 7, Issue , 2016, Pages

  Ji, Yan Xiao ^a,b,c   Zhang, Peng ^a,b,c   Zhang, Xiao Jing ^a,b,c   Zhao, Yi Chao ^a   Deng, Ke Qiong ^a,b,c   Jiang, Xi ^a,b,c   Wang, Pi Xiao ^a,b,c   Huang, Zan ^b   Li, Hongliang ^a,b,c  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN PROTEIN LIGASE E3; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN BINDING; UBIQUITIN PROTEIN LIGASE;

ENZYME ACTIVITY; GENE EXPRESSION; OXYGEN; PATHOLOGY; PHENOTYPE; PROTEIN; REACTION KINETICS; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; ECHOCARDIOGRAPHY; GENE OVEREXPRESSION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRESSURE; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CELL CULTURE; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; METABOLISM; NEWBORN; PATHOLOGY; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

MURINAE; MUS;

ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; HEK293 CELLS; HUMANS; MAP KINASE KINASE KINASES; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTEIN BINDING; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84973446475     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11267     Document Type: Article

References (70)

1. Hill, J. A. & Olson, E. N. Cardiac plasticity. N. Engl. J. Med. 358, 1370-1380 (2008).
2. Jiang, D. S. et al. IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nat. Commun. 5, 3303 (2014).
3. Putinski, C. et al. Intrinsic-mediated caspase activation is essential for cardiomyocyte hypertrophy. Proc. Natl Acad. Sci. USA 110, E4079-E4087 (2013).
4. Xie, P. TRAF molecules in cell signaling and in human diseases. J. Mol. Signal. 8, 7 (2013).
5. Xu, L. G., Li, L. Y. & Shu, H. B. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J. Biol. Chem. 279, 17278-17282 (2004).
6. Bian, Z. et al. Disruption of tumor necrosis factor receptor associated factor 5 exacerbates pressure overload cardiac hypertrophy and fibrosis. J. Cell. Biochem. 115, 349-358 (2014).
7. Jiang, X. et al. Tumor necrosis factor receptor-associated factor 3 is a positive regulator of pathological cardiac hypertrophy. Hypertension 66, 356-367 (2015).
8. Divakaran, V. G. et al. Tumor necrosis factor receptor-associated factor 2 signaling provokes adverse cardiac remodeling in the adult mammalian heart. Circ. Heart Fail. 6, 535-543 (2013).
9. Lomaga, M. A. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024 (1999).
10. Naito, A. et al. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia. Proc. Natl Acad. Sci. USA 99, 8766-8771 (2002).
11. Mu, Y. et al. TRAF6 ubiquitinates TGFbeta type I receptor to promote its cleavage and nuclear translocation in cancer. Nat. Commun. 2, 330 (2011).
12. Alvarez, S. E. et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465, 1084-1088 (2010).
13. Sebban-Benin, H. et al. Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti. Hum. Mol. Genet. 16, 2805-2815 (2007).
14. Kawai, T. et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5, 1061-1068 (2004).
15. Balkhi, M. Y., Fitzgerald, K. A. & Pitha, P. M. Functional regulation of MyD88-activated interferon regulatory factor 5 by K63-linked polyubiquitination. Mol. Cell. Biol. 28, 7296-7308 (2008).
16. Jiang, D. S. et al. Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy. Hypertension 63, 713-722 (2014).
17. Cao, Z., Xiong, J., Takeuchi, M., Kurama, T. & Goeddel, D. V. TRAF6 is a signal transducer for interleukin-1. Nature 383, 443-446 (1996).
18. Zhang, Y. et al. Ablation of Akt2 protects against lipopolysaccharide-induced cardiac dysfunction: role of Akt ubiquitination E3 ligase TRAF6. J. Mol. Cell. Cardiol. 74, 76-87 (2014).
19. Chen, J., Wang, Z. & Wu, T. Shenqi fuzheng injection improves cvb3-induced myocarditis via inhibiting traf6 expression. Cell. Mol. Biol. (Noisy-le-grand) 59(Suppl): Ol1826-Ol1834 (2013).
20. Zhu, L. H. et al. Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling. Free Radic. Biol. Med. 48, 471-482 (2010).
21. Hirotani, S. et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105, 509-515 (2002).
22. Imai, Y. et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-249 (2008).
23. Matsuzawa, A. et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat. Immunol. 6, 587-592 (2005).
24. Fujino, G. et al. Thioredoxin and TRAF family proteins regulate reactive oxygen species-dependent activation of ASK1 through reciprocal modulation of the N-terminal homophilic interaction of ASK1. Mol. Cell. Biol. 27, 8152-8163 (2007).
25. McCalmon, S. A. et al. Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2. Circ. Res. 106, 952-960 (2010).
26. Walsh, M. C., Lee, J. & Choi, Y. Tumor necrosis factor receptor-associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system. Immunol. Rev. 266, 72-92 (2015).
27. Chen, K. et al. Vinexin-beta protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway. Basic Res. Cardiol. 108, 338 (2013).
28. Min, W. et al. AIP1 recruits phosphatase PP2A to ASK1 in tumor necrosis factor-induced ASK1-JNK activation. Circ. Res. 102, 840-848 (2008).
29. Pal, A. et al. CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer. Cancer Res. 72, 4818-4828 (2012).
30. Ajibade, A. A., Wang, H. Y. & Wang, R. F. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol. 34, 307-316 (2013).
31. Yamashita, M. et al. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol. Cell 31, 918-924 (2008).
32. Sorrentino, A. et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 10, 1199-1207 (2008).
33. Kanayama, A. et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 15, 535-548 (2004).
34. Fan, Y., Yu, Y., Mao, R., Zhang, H. & Yang, J. TAK1 Lys-158 but not Lys-209 is required for IL-1beta-induced Lys63-linked TAK1 polyubiquitination and IKK/NF-kappaB activation. Cell Signal. 23, 660-665 (2011).
35. Landstrom, M. The TAK1-TRAF6 signalling pathway. Int. J. Biochem. Cell Biol. 42, 585-589 (2010).
36. Lamothe, B. et al. Site-specific Lys-63-linked tumor necrosis factor receptorassociated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J. Biol. Chem. 282, 4102-4112 (2007).
37. Byrne, J. A. et al. Contrasting roles of NADPH oxidase isoforms in pressureoverload versus angiotensin II-induced cardiac hypertrophy. Circ. Res. 93, 802-805 (2003).
38. Sabri, A., Hughie, H. H. & Lucchesi, P. A. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid. Redox Signal. 5, 731-740 (2003).
39. Dai, L., Aye Thu, C., Liu, X. Y., Xi, J. & Cheung, P. C. TAK1 more than just innate immunity. IUBMB Life 64, 825-834 (2012).
40. Watkins, S. J., Borthwick, G. M., Oakenfull, R., Robson, A. & Arthur, H. M. Angiotensin II-induced cardiomyocyte hypertrophy in vitro is TAK1-dependent and Smad2/3-independent. Hypertens. Res. 35, 393-398 (2012).
41. Watkins, S. J., Jonker, L. & Arthur, H. M. A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy. Cardiovasc. Res. 69, 432-439 (2006).
42. Huang, H. et al. Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension 56, 232-239 (2010).
43. Zhang, D. et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 6, 556-563 (2000).
44. Takaesu, G. et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 5, 649-658 (2000).
45. Xia, Z. P. et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 461, 114-119 (2009).
46. Li, L. et al. Transforming growth factor beta-activated kinase 1 signaling pathway critically regulates myocardial survival and remodeling. Circulation 130, 2162-2172 (2014).
47. Liu, H. H., Xie, M., Schneider, M. D. & Chen, Z. J. Essential role of TAK1 in thymocyte development and activation. Proc. Natl Acad. Sci. USA 103, 11677-11682 (2006).
48. Sato, S. et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6, 1087-1095 (2005).
49. Jadrich, J. L., O'Connor, M. B. & Coucouvanis, E. The TGF beta activated kinase TAK1 regulates vascular development in vivo. Development 133, 1529-1541 (2006).
50. Monzen, K. et al. Smads, TAK1, and their common target ATF-2 play a critical role in cardiomyocyte differentiation. J. Cell Biol. 153, 687-698 (2001).
51. ten Dijke, P. & Arthur, H. M. Extracellular control of TGFbeta signalling in vascular development and disease. Nat. Rev. Mol. Cell. Biol. 8, 857-869 (2007).
52. Omori, E. et al. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J. Biol. Chem. 281, 19610-19617 (2006).
53. Paul, P. K. et al. The E3 ubiquitin ligase TRAF6 intercedes in starvationinduced skeletal muscle atrophy through multiple mechanisms. Mol. Cell. Biol. 32, 1248-1259 (2012).
54. Cao, D. J. et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc. Natl Acad. Sci. USA 108, 4123-4128 (2011).
55. Jiang, D. S. et al. Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload. Hypertension 64, 77-86 (2014).
56. Jiang, D. S. et al. Signal regulatory protein-alpha protects against cardiac hypertrophy via the disruption of toll-like receptor 4 signaling. Hypertension 63, 96-104 (2014).
57. Li, Y. Q. et al. Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice. Acta Pharmacol. Sin. 34, 352-359 (2013).
58. Zhang, Y. et al. Dickkopf-3 attenuates pressure overload-induced cardiac remodelling. Cardiovasc. Res. 102, 35-45 (2014).
59. Liu, Y. et al. Toll-interacting protein (Tollip) negatively regulates pressure overload-induced ventricular hypertrophy in mice. Cardiovasc. Res. 101, 87-96 (2014).
60. Li, H. et al. Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc. Natl Acad. Sci. USA 107, 13818-13823 (2010).
61. Jiang, D. S. et al. Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin. Hypertension 63, 119-127 (2014).
62. Lee, I. T. et al. Lipoteichoic acid induces HO-1 expression via the TLR2/MyD88/c-Src/NADPH oxidase pathway and Nrf2 in human tracheal smooth muscle cells. J. Immunol. 181, 5098-5110 (2008).
63. Chae, H. J. et al. Catalase protects cardiomyocytes via its inhibition of nitric oxide synthesis. Nitric Oxide 14, 189-199 (2006).
64. Ma, J. et al. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and-independent pathways. Cardiovasc. Res. 97, 77-87 (2013).
65. Lee, N. K. et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106, 852-859 (2005).
66. Deng, S. et al. Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic. Biol. Med. 42, 466-473 (2007).
67. Borchi, E. et al. Enhanced ROS production by NADPH oxidase is correlated to changes in antioxidant enzyme activity in human heart failure. Biochim. Biophys. Acta 1802, 331-338 (2010).
68. Moritz, F. et al. Role of reactive oxygen species in cocaine-induced cardiac dysfunction. Cardiovasc. Res. 59, 834-843 (2003).
69. Lu, J. et al. Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res. Cardiol. 108, 326 (2013).
70. Qin, Y. et al. RNF26 temporally regulates virus-triggered type I interferon induction by two distinct mechanisms. PLoS Pathog. 10, e1004358 (2014).